🇺🇸 OGN — Organon & Co.

Salud Mantener
← Volver

Precio actual

13,83 USD

Máx. histórico

39,36

1708 días

Caída desde máximo

-64,86%

Rango 52 semanas

5,69 – 13,87

Variación hoy

-0,14%

Cierre anterior

13,85

Rango de hoy

13,83 – 13,87

Volumen hoy

2.172.358

Peor caída histórica

-82,69%

02/03/2022 → 30/03/2026

Aún sin recuperar

Volatilidad anualizada ⓘ

46,95%

Información
Nombre completo
Organon & Co.
Divisa
USD
Mercado
NYSE
Sector
Salud
Industria
Drug Manufacturers - General
Empleados
10.000
PER ⓘ
17,73 (puede no estar actualizado)
Dividend yield
0,58% (puede no estar actualizado)
Precio objetivo analistas
10,33 USD (puede no estar actualizado)
Primera cotización
14/05/2021
Precio actualizado
hace 2 horas
Sobre la empresa

Organon & Co. develops and delivers women health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, China, Latin America, the Middle East, Russia, Africa, and internationally. The company's women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, Marvelon, and Mercilon to prevent pregnancy; Follistim AQ, which is used to promote development of ovarian follicles; Elonva, a follicle stimulant; Ganirelix acetate injection, an injectable antagonist; Jada for abnormal postpartum uterine bleeding and hemorrhage; and Xaciato for bacterial vaginosis. Its biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; oncology products, including Ontruzant and Aybintio; Bildyos and Bilprevda, a recombinant anti-RANKL human monoclonal antibodies; and Poherdy, a neu receptor antagonist. The company also offers cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Inegy, Atozet, Rosuzet, and Zocor brands; Cozaar and Hyzaar for hypertension; respiratory products to control and prevent asthma symptoms under the Singulair, Dulera, Zenhale, and Asmanex brands, as well as seasonal allergic rhinitis under the Nasonex, Clarinex, and Aerius brands. In addition, it provides dermatology products under the Vtama, Diprosone, and Elocon brand; bone health products under the Fosamax brand; and non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brands, as well as Proscar for symptomatic benign prostatic hyperplasia; and Propecia for male pattern hair loss. The company serves drug wholesalers and retailers, hospitals, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions. Organon & Co. was founded in 1923 and is headquartered in Jersey City, New Jersey.

Dividendos repartidos Total últimos 12 meses: 0,0800 USD · Yield: 0,58%
Fecha de pago Importe por participación
14/08/2026 0,0200 USD
11/05/2026 0,0200 USD
23/02/2026 0,0200 USD
20/11/2025 0,0200 USD
15/08/2025 0,0200 USD
12/05/2025 0,0200 USD
24/02/2025 0,2800 USD
12/11/2024 0,2800 USD
16/08/2024 0,2800 USD
10/05/2024 0,2800 USD
23/02/2024 0,2800 USD
10/11/2023 0,2800 USD
17/08/2023 0,2800 USD
12/05/2023 0,2800 USD
24/02/2023 0,2800 USD
Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
21/02/2023 26,01 27,08 25,96 27,04 +3,92% 4,30% 3.100.400
17/02/2023 24,68 26,38 24,11 26,02 +4,62% 9,20% 5.159.000
16/02/2023 27,84 28,15 24,56 24,87 -15,00% 12,91% 9.270.200
15/02/2023 28,83 29,37 28,73 29,26 +0,45% 2,20% 1.782.500
14/02/2023 29,52 29,55 29,07 29,13 -1,19% 1,63% 1.423.100
13/02/2023 28,95 29,52 28,69 29,48 +1,59% 2,87% 1.465.300
10/02/2023 28,99 29,20 28,88 29,02 -0,14% 1,12% 1.418.400
09/02/2023 29,77 29,84 28,99 29,06 -2,09% 2,87% 1.258.000
08/02/2023 29,80 29,83 29,51 29,68 -0,54% 1,06% 809.200
07/02/2023 29,47 29,88 29,21 29,84 +0,88% 2,26% 826.100
06/02/2023 29,60 29,73 29,21 29,58 -0,60% 1,76% 1.276.200
03/02/2023 30,25 30,48 29,74 29,76 -2,14% 2,45% 1.032.000
02/02/2023 30,30 30,50 30,14 30,41 +0,33% 1,19% 1.228.500
01/02/2023 30,00 30,49 29,92 30,31 +0,60% 1,90% 1.452.200
31/01/2023 29,51 30,18 29,46 30,13 +1,89% 2,46% 4.841.000
30/01/2023 29,71 29,85 29,35 29,57 -1,24% 1,68% 1.696.300
27/01/2023 30,15 30,44 29,84 29,94 -1,25% 2,01% 1.590.600
26/01/2023 30,60 30,82 30,11 30,32 -1,04% 2,32% 1.432.000
25/01/2023 31,47 31,47 30,48 30,64 -2,45% 3,16% 1.364.500
24/01/2023 31,80 31,90 30,99 31,41 -1,87% 2,86% 1.401.200
23/01/2023 31,46 32,07 31,35 32,01 +2,14% 2,30% 1.434.700
20/01/2023 31,43 31,59 31,01 31,34 -0,22% 1,85% 1.556.900
19/01/2023 31,64 31,84 31,24 31,41 -1,66% 1,90% 1.904.300
18/01/2023 32,26 32,43 31,85 31,94 -0,44% 1,80% 2.385.500
17/01/2023 32,13 32,30 31,80 32,08 +0,06% 1,56% 2.744.300
13/01/2023 31,43 32,12 31,39 32,06 +2,17% 2,34% 2.578.300
12/01/2023 30,69 31,49 30,59 31,38 +2,42% 2,92% 2.715.400
11/01/2023 30,30 30,70 29,94 30,64 +1,73% 2,51% 2.244.500
10/01/2023 29,69 30,28 29,37 30,12 +1,83% 3,05% 2.057.400
09/01/2023 29,14 30,04 29,07 29,58 +1,48% 3,33% 1.696.900